Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet (NYSE: ZBH) has received FDA 510(k) clearance for its Persona® Revision SoluTion™ Femur, a revolutionary revision knee implant designed for patients with metal sensitivities. The implant is part of the comprehensive Persona Revision Knee System and features a proprietary surface-hardening treatment for enhanced wear performance.
The innovation addresses a significant medical need, as metal hypersensitivity affects 10-15% of the general population and up to 25% of patients with metallic implants. The implant is made exclusively from Tivanium® alloy with the Ti-Nidium Surface Hardening Process, offering an alternative free from common metal allergens like Nickel, Cobalt, and Chromium.
The product will be available commercially in the U.S. in Q3 2025, offering standard and plus sizes to address flexion instability and soft tissue balancing while minimizing implant overhang.
Zimmer Biomet (NYSE and SIX: ZBH) has appointed Kristen Cardillo as Senior Vice President, Chief Communications Officer, effective March 10, 2025. Reporting to President and CEO Ivan Tornos, Cardillo will lead the company's global communications strategy and stakeholder engagement initiatives.
Cardillo joins from 10x Genomics, where she served as Vice President of Corporate Communications. Previously, she held the position of Vice President of Global Communications and Public Relations at Becton, Dickinson and Company (BD), managing internal communications, public relations, social media, and financial communications. Her earlier career includes roles at CareFusion and Cardinal Health. She holds a Bachelor of Science degree in Telecommunications from Ohio University.
Zimmer Biomet (NYSE and SIX: ZBH) has announced its participation in the 27th Annual Barclays Healthcare Conference. The company's management team will deliver a presentation on Thursday, March 13, 2025, at 9:30 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website at https://investor.zimmerbiomet.com. The presentation will be archived for later viewing following the conference.
Zimmer Biomet (NYSE and SIX: ZBH) has appointed Jehanzeb Noor as Senior Vice President, Chief Strategy, Innovation and Business Development Officer, reporting to CEO Ivan Tornos. In his new role, Noor will lead strategy development, oversee M&A activities including the Paragon 28 acquisition integration, and manage research and product development organizations. He will also serve as Chief of Staff to the CEO.
Noor joins from Trivium, where he served as President and Managing Director for Europe, Africa, and Asia, leading transformation initiatives for margin and cash expansion. His previous experience includes serving as CEO of Smiths Medical and roles at Amcor, McKinsey, Ford Motor Company, and Constellation Energy. Noor holds multiple degrees from MIT, including an MS in Product Development and BS degrees in Finance and Mechanical Engineering.
Zimmer Biomet (NYSE: ZBH) has launched the 'You'll Be Back' campaign featuring Arnold Schwarzenegger as Chief Movement Officer. The initiative creates an online community at YoullBeBack.com for people suffering from joint pain, allowing them to share their stories and connect with qualified physicians.
The campaign aims to empower individuals with resources for making informed mobility choices. Selected community members will be featured in a motivational docuseries. According to CDC data, nearly 27 million Americans over 65 are affected by osteoarthritis, the primary cause for joint replacement. By 2030, an estimated 4 million people in the U.S. will need joint replacement procedures.
Zimmer Biomet Holdings (NYSE and SIX: ZBH) has announced its quarterly dividend for Q1 2025. The Board of Directors has approved a cash dividend of $0.24 per share, which will be distributed to stockholders on April 30, 2025. Shareholders must be on record by the close of business on March 31, 2025 to be eligible for this dividend payment.
Zimmer Biomet (NYSE: ZBH) announced significant changes to its Board of Directors. Christopher Begley will retire as Non-Executive Chairman at the stockholders' annual meeting on May 29, 2025, due to mandatory retirement age requirements.
Current President and CEO Ivan Tornos will assume the role of Chairman of the Board following Begley's departure. Additionally, Michael Farrell, who has served on the board since 2014, will become Lead Independent Director.
Begley has been a board member since 2012, serving as Non-Executive Chairman since August 2023 and previously as Lead Independent Director from May 2021. He also participated in various committees including Corporate Governance, Compensation and Management Development, and chaired the Quality, Regulatory and Technology Committee.
Zimmer Biomet reported strong Q4 2024 financial results with net sales of $2.023 billion, up 4.3% year-over-year (4.9% constant currency). Full-year net sales reached $7.679 billion, increasing 3.8% (4.8% constant currency).
Q4 net earnings were $239.4 million ($462.4 million adjusted), with diluted EPS of $1.20 ($2.31 adjusted). Full-year net earnings totaled $903.8 million ($1.630 billion adjusted), with diluted EPS of $4.43 ($8.00 adjusted).
The company announced plans to acquire Paragon 28, expanding into the $5 billion foot and ankle segment. Notable achievements include FDA approval for the Oxford® Cementless Partial Knee and OsseoFit™ Stemless Shoulder System. For 2025, the company projects revenue growth of 1.0-3.5% (3.0-5.0% constant currency) and adjusted EPS of $8.15-$8.35.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Paragon 28 (NYSE: FNA) for $13.00 per share in cash, representing an equity value of approximately $1.1 billion and enterprise value of $1.2 billion. Paragon 28 shareholders will receive a non-tradeable contingent value right (CVR) worth up to $1.00 per share if certain revenue milestones are achieved in fiscal year 2026.
The acquisition expands Zimmer Biomet's presence in the ~$5 billion foot and ankle segment. Paragon 28, established in 2010, offers surgical solutions across major foot and ankle segments. The transaction is expected to immediately accelerate Zimmer Biomet's revenue growth, with Paragon 28's projected 2024 net revenue between $255.9-256.2 million, representing 18.2-18.4% growth.
The deal is anticipated to close in first half of 2025, subject to regulatory approvals and Paragon 28 stockholder approval. It is expected to be approximately 3% dilutive to adjusted EPS in 2025, 1% dilutive in 2026, and accretive within 24 months of closing.
Zimmer Biomet Holdings (NYSE and SIX: ZBH) has scheduled its fourth quarter 2024 financial results conference call for Thursday, February 6, 2025, at 8:30 a.m. ET. The company will release its quarterly results news release earlier that day at 6:30 a.m. ET.
The earnings call will be accessible through a live audio webcast on Zimmer Biomet's Investor Relations website, with a replay option available after the call. For those wishing to participate via phone, U.S. and Canadian participants can dial (888) 204-4368, while international callers should use +1 (323) 994-2093, both using conference ID 5103691.
FAQ
What is the current stock price of Zimmer Biomet (ZBH)?
What is the market cap of Zimmer Biomet (ZBH)?
